Molecular Pharma-Biotechnology

The increasing availability of DNA sequences, stiiictural data and analyses of interactions is opening a plethora of new targets for therapeutic intervention. 

DNA may be the target of sequence changes (gene therapy), or interact witli small molecules (RNA, PNA, pharmaceuticals, peptides) or large proteins RNA may be target for small molecules, and proteins for small molecules or irrteracting large ones. 

Structural genomics requhes methods to determine the three-dimensional straictnres of proteins and complexes. 

Tlie application of genomic technologies to the study of infectious agents is yielding results for anti-infective therapies. Tire combination of sequencing, bacterial genomics. 

The logical and necessary successors to the Human Genome Project, which delivers primary seqnence data, are comparable efforts in bioinformatics (to understand the meaning of the seqnences), in structural studies (to understand the structures and interactions of molecules derived from gene sequences) and the molecular design of interacting (small) molecules as well as (finally ) the overall biological systems for validation, verification and application (e.g., mouse, zebra fish. Drosophila and hnman).  

---